VivoSim Labs, INC. — Form S-1
Filed July 31, 2026 · analyzed by the Registration Agent
S-1
— Neutral
significance 28/100
What the filing says
On July 16, 2026, VivoSim Labs issued 4.7M pre-funded warrants (exercise price $0.001/share) and 4.7M common warrants (exercise price $0.85/share) to Armistice Capital Master Fund Ltd. in a private placement. This S-1 registration allows Armistice to resell up to 9.4M underlying common shares. Armistice already held 5.2M shares (31.18% ownership) and may own up to 14.6M shares post-exercise. The company raised capital via warrant issuance rather than direct equity; it receives no proceeds from warrant resales, only from cash exercises.
Why this rating
Warrant issuance is standard financing for micro-cap biotech ($7.5M market cap). Dilution is material (~9.4M new shares, ~56% increase to 16.8M outstanding), but typical for survival-stage company. No revenue impact stated; warrants are financing, not operations. Armistice's controlling position unchanged.
Extracted items
- 2.02 results / earnings
- 7.01 Reg FD disclosure
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.